Your browser doesn't support javascript.
loading
Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma.
Brammer, Jonathan E; Braunstein, Zachary; Katapadi, Aashish; Porter, Kyle; Biersmith, Michael; Guha, Avirup; Vasu, Sumithira; Yildiz, Vedat O; Smith, Sakima A; Buck, Benjamin; Haddad, Devin; Gumina, Richard; William, Basem M; Penza, Sam; Saad, Ayman; Denlinger, Nathan; Vallakati, Ajay; Baliga, Ragavendra; Benza, Raymond; Binkley, Philip; Wei, Lai; Mocarski, Mason; Devine, Steven M; Jaglowski, Samantha; Addison, Daniel.
Afiliação
  • Brammer JE; Bone Marrow Transplantation and Cellular Therapies Program, Division of Hematology, The Ohio State University James Cancer Hospital, Columbus, Ohio, USA.
  • Braunstein Z; Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
  • Katapadi A; Cardio-Oncology Program, Division of Cardiology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
  • Porter K; Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
  • Biersmith M; Cardio-Oncology Program, Division of Cardiology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
  • Guha A; Cardio-Oncology Program, Division of Cardiology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
  • Vasu S; Cardiology, University Hospitals Harrington Heart & Vascular Institute, Cleveland, Ohio, USA.
  • Yildiz VO; Bone Marrow Transplantation and Cellular Therapies Program, Division of Hematology, The Ohio State University James Cancer Hospital, Columbus, Ohio, USA.
  • Smith SA; Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
  • Buck B; Cardio-Oncology Program, Division of Cardiology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
  • Haddad D; Cardio-Oncology Program, Division of Cardiology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
  • Gumina R; Cardio-Oncology Program, Division of Cardiology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
  • William BM; Cardio-Oncology Program, Division of Cardiology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
  • Penza S; Bone Marrow Transplantation and Cellular Therapies Program, Division of Hematology, The Ohio State University James Cancer Hospital, Columbus, Ohio, USA.
  • Saad A; Bone Marrow Transplantation and Cellular Therapies Program, Division of Hematology, The Ohio State University James Cancer Hospital, Columbus, Ohio, USA.
  • Denlinger N; Bone Marrow Transplantation and Cellular Therapies Program, Division of Hematology, The Ohio State University James Cancer Hospital, Columbus, Ohio, USA.
  • Vallakati A; Division of Hematology, The Ohio State University James Cancer Hospital, Columbus, Ohio, USA.
  • Baliga R; Cardio-Oncology Program, Division of Cardiology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
  • Benza R; Cardio-Oncology Program, Division of Cardiology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
  • Binkley P; Cardio-Oncology Program, Division of Cardiology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
  • Wei L; Cardio-Oncology Program, Division of Cardiology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
  • Mocarski M; Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
  • Devine SM; Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
  • Jaglowski S; National Marrow Donor Program, Minneapolis, Minnesota, USA.
  • Addison D; Bone Marrow Transplantation and Cellular Therapies Program, Division of Hematology, The Ohio State University James Cancer Hospital, Columbus, Ohio, USA.
J Immunother Cancer ; 9(8)2021 08.
Article em En | MEDLINE | ID: mdl-34429331
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Antígenos de Linfócitos T / Síndromes Neurotóxicas / Imunoterapia / Linfoma Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: J Immunother Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Antígenos de Linfócitos T / Síndromes Neurotóxicas / Imunoterapia / Linfoma Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: J Immunother Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos